Glutamate and the Neural Basis of the Subjective Effects of Ketamine: A Pharmaco-Magnetic Resonance Imaging Study
This double-blind, placebo-controlled, randomised, crossover, counterbalanced study (n=33) investigated whether ketamine-induced (20.5mg/70kg) dissociative mental state is blocked via pretreatment with the glutamate release inhibitor lamotrigine (300mg/70kg). Ketamine produced dissociative effects which corresponded to decreased activity in the ventromedial frontal cortex, including the orbitofrontal cortex and subgenual cingulate, and increased activity in mid-posterior cingulate, thalamus, and temporal cortical regions. Most of these effects were mitigated by lamotrigine, thereby indicating that the dissociative effects of ketamine are mediated by glutamate release.
Abstract
Context
Ketamine evokes psychosis like symptoms, and its primary action is to impair N-methyl-D-aspartate glutamate receptor neurotransmission, but it also induces secondary increases in glutamate release.
Objectives
To identify the sites of action of ketamine in inducing symptoms and to determine the role of increased glutamate release using the glutamate release inhibitor lamotrigine.
Design
Two experiments with different participants were performed using a double-blind, placebo-controlled, randomized, crossover, counterbalanced-order design. In the first experiment, the effect of intravenous ketamine hydrochloride on regional blood oxygenation level- dependent (BOLD) signal and correlated symptoms was compared with intravenous saline placebo. In the second experiment, pretreatment with lamotrigine was compared with placebo to identify which effects of ketamine are mediated by increased glutamate release.
Setting
Wellcome Trust Clinical Research Facility, Manchester, England.
Participants
Thirty-three healthy, right-handed men were recruited by advertisements.
Interventions
In experiment 1, participants were given intravenous ketamine (1-minute bolus of 0.26 mg/kg, followed by a maintenance infusion of 0.25 mg/kg/h for the remainder of the session) or placebo (0.9% saline solution). In experiment 2, participants were pretreated with 300 mg of lamotrigine or placebo and then were given the same doses of ketamine as in experiment 1. MainOutcome Measures: Regional BOLD signal changes during ketamine or placebo infusion and Brief Psychiatric Rating Scale and Clinician-Administered Dissociative States Scale scores.
Results
Ketamine induced a rapid, focal, and unexpected decrease in ventromedial frontal cortex, including orbitofrontal cortex and subgenual cingulate, which strongly predicted its dissociative effects and increased activity in mid-posterior cingulate, thalamus, and temporal cortical regions (r=0.90). Activations correlated with Brief Psychiatric Rating Scale psychosis scores. Lamotrigine pretreatment prevented many of the BOLD signal changes and the symptoms.
Conclusions
These 2 changes may underpin 2 fundamental processes of psychosis: abnormal perceptual experiences and impaired cognitive-emotional evaluation of their significance. The results are compatible with the theory that the neural and subjective effects of ketamine involve increased glutamate release.
Research Summary of 'Glutamate and the Neural Basis of the Subjective Effects of Ketamine: A Pharmaco-Magnetic Resonance Imaging Study'
Introduction
Impaired signalling through N-methyl-D-aspartate (NMDA) glutamate receptors has been implicated in the pathogenesis of schizophrenia because NMDA antagonists such as phencyclidine and ketamine produce psychosislike symptoms in healthy volunteers and exacerbate symptoms in patients. Previous animal and human work indicates that NMDA blockade can both reduce inhibitory GABAergic interneuron activity and provoke secondary increases in cortical glutamate release; this glutamate surge has been linked experimentally to behavioural effects and may act via non-NMDA receptors. Positron emission tomography studies of ketamine in humans have reported frontal and sometimes anterior cingulate effects, but have not reproduced posterior cingulate, retrosplenial or hippocampal findings seen in rodents, possibly because of dose/timing differences and the temporal resolution of PET methods. Deakin and colleagues set out to map the immediate neural correlates of ketamine's subjective effects in healthy volunteers using continuous functional magnetic resonance imaging (fMRI) and to test whether those effects are mediated by increased glutamate release. They performed two double-blind, placebo-controlled, randomized, within-subject crossover experiments: first comparing intravenous ketamine with saline placebo, and second testing whether pretreatment with the glutamate-release inhibitor lamotrigine (300 mg) attenuated ketamine's behavioural and BOLD (blood oxygenation level-dependent) signal effects. The investigators used a minute-by-minute phMRI pseudoblock analysis to capture rapid, regionally specific time courses of drug effects during the early infusion period.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Author
- APA Citation
Deakin, J. F. W., Lees, J., McKie, S., Hallak, J. E. C., Williams, S. R., & Dursun, S. M. (2008). Glutamate and the Neural Basis of the Subjective Effects of Ketamine: A Pharmaco-Magnetic Resonance Imaging Study. Archives of General Psychiatry, 65(2), 154. https://doi.org/10.1001/archgenpsychiatry.2007.37
References (1)
Papers cited by this study that are also in Blossom
Berman, R. M., Cappiello, A., Anand, A. et al. · Biological Psychiatry (2000)
Cited By (18)
Papers in Blossom that reference this study
Rodrigues, L. S., Rossi, G. N., Guerra, L. T. L. et al. · Journal of Clinical Psychopharmacology (2024)
Veraart, J. K. E., Smith-Apeldoorn, S. Y., Bakker, I. M. et al. · International Journal of Neuropsychopharmacology (2021)
Alexander, L., Jelen, L. A., Mehta, M. A. et al. · Neuroscience and Biobehavioral Reviews (2021)
Muthukumaraswamy, S., Forsyth, B., Lumley, T. · Expert Review of Clinical Pharmacology (2021)
Walter, M., Derntl, B., Hornung, J. et al. · Frontiers in Neuroscience (2019)
Ionescu, D. F., Felicione, J. M., Gosai, A. et al. · Harvard Review of Psychiatry (2018)
Carbonaro, T. M., Hurwitz, E., Johnson, M. W. · Psychopharmacology (2017)
Abdallah, C. G., Averill, C. L., Salas, R. et al. · Biological Psychiatry (2017)
Millière, R. · Frontiers in Human Neuroscience (2017)
Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)
Show all 18 papersShow fewer
Joules, R., Doyle, &. O. M., Schwarz, A. J. et al. · Psychopharmacology (2015)
Majic, T., Schmidt, T. T., Gallinat, J. · Journal of Clinical Psychopharmacology (2015)
Steeds, H., Carhart-Harris, R. L., Stone, J. M. · Therapeutic Advances in Psychopharmacology (2014)
Ari, A., Abdallah, C. G., Sanacora, G. et al. · Annual Review of Medicine (2014)
Carhart-Harris, R. L., Leech, R., Shanahan, M. et al. · Frontiers in Human Neuroscience (2014)
Frohlich, J, Van Horn, J. D. · Journal of Psychopharmacology (2013)
Corlett, P. R., Honey, G. D., Krystal, J. H. et al. · Neuropsychopharmacology (2010)
Carhart-Harris, R. L., Nutt, D. J. · Journal of Substance Use (2010)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.